Prognostic value of immunohistochemical expression of HER-2eu in patients with lung carcinoma

摘要

Background. The amplification and the overexpression of the Her-2eu gene have been shown in certain human tumours and are postulated to be important in human carcinogenesis. In this study we evaluated the expression of HER-2eu gene in patients with lung carcinoma (LC) and assessed its prognostic significance.Patients and methods. HER-2eu expression was determined in 127 LC patients using immunohistochemistry (IHC) performed on paraffin-embedded section - Hercep Testa?￠ (DAKO).Results. The overall HER-2eu expression was seen in 36 (28.35%) of 127 LC patients. According to the histological type, HER-2eu overexpression was detected in 12 patients with adenocarcinomas (60%), in 19 patients with squamous cell carcinomas (31.14%), in 4 patients with small cell-lung carcinomas (10%) and in 1 patient with other carcinomas (16.66%). Only in patients with small cell-lung carcinomas HER-2eu overexpression was in correlation with the stage of the disease (p0.001). The patients with HER-2eu positive expression were associated with a significantly shorter survival compared with those who were HER-2eu negative (log rank, p0.002).Conclusions. These observations suggest that HER-2eu positivity may serve as a prognostic indicator in patients with LC. HER-2eu plays a role in identifying patients at risk for the shortened survival, who may benefit from a more aggressive therapy.